You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 康希諾生物6連升累漲近40%創新高 市值突破110億港元
格隆匯 11-25 16:16
格隆匯11月25日丨康希諾生物-B(6185.HK)今日續漲,暫六日連升累漲逾39%,盤中觸及50.15港元創上市新高。現報49.55港元,漲8.42%,暫成交3959萬港元,最新總市值110.3億港元。康希諾生物上週五(22日)午間發公告稱,國家藥監局於近日受理了該公司自主研發的四價流腦結合疫苗“曼海欣”的新藥註冊申請,成為我國首款進入新藥註冊審理程序的該種疫苗。此外,公司曾於10月14日公佈,擬發行不超過2480萬股A股股票並申請科創板上市,所募集資金在扣除發行費用後將用於投入生產基地二期建設、疫苗研發等項目。值得一提的是,康希諾生物於今年3月28日在港上市,現較發行價22港元已累漲逾125%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account